title: Alterations in neural pathways to the urinary bladder of the rat in response to streptozotocin-induced diabetes.
abstract: Voiding dysfunction in diabetics has been attributed to a variety of causes including an axonopathy in autonomic pathways to the urinary bladder. The present study was undertaken to determine whether changes occurred in afferent and efferent neurons supplying bladders of streptozotocin (STZ)-induced diabetic rats. Nine weeks after STZ treatment, the mean cross-sectional area for retrogradely labeled (Fluoro-Gold) bladder neurons in the major pelvic ganglion (MPG) was greater in diabetics (364 microns 2) than controls (300 microns 2). The number of labeled neurons was similar in these groups. In contrast, mean cross-sectional areas of bladder afferent neurons labeled with WGA-HRP in the L6 and S1 dorsal root ganglia (DRG) were smaller (393 microns 2) in diabetics than in normal rats (528 microns 2). In addition, very few DRG neurons were labeled in STZ-treated rats and transganglionic labeling of bladder afferent projections in the L6 and S1 spinal cord with WGA-HRP was sparse. Radioimmunoassay studies revealed that substance P was reduced by 70% in the MPG and by 40% in L6 DRG, yet this peptide was unchanged in the bladders of diabetic rats. The amounts of VIP in the MPG and DRG of diabetics and controls were similar, while VIP in the bladder was increased in diabetics. These observations indicate that both afferent and efferent neurons innervating the urinary bladder are altered in the STZ-induced diabetic rat. In addition, axonal transport in visceral afferent pathways may be disrupted.
authors.affiliation: Department of Urology, University of Virginia Health Sciences Center.
authors.forename: W D
authors.initials: WD
authors.lastname: Steers
authors.forename: A M
authors.initials: AM
authors.lastname: Mackway-Gerardi
authors.forename: J
authors.initials: J
authors.lastname: Ciambotti
authors.forename: W C
authors.initials: WC
authors.lastname: de Groat
mesh_terms: D000344:Afferent Pathways / Q000473:pathology; D000818:Animals; D001369:Axons / Q000502:physiology; D003921:Diabetes Mellitus, Experimental / Q000473:pathology*; D004231:Diuresis / Q000502:physiology; D004525:Efferent Pathways / Q000473:pathology; D005260:Female; D005456:Fluorescent Dyes; D005725:Ganglia, Autonomic / Q000502:physiology; D005727:Ganglia, Spinal / Q000378:metabolism; D006651:Histocytochemistry; D006735:Horseradish Peroxidase; D010388:Pelvis / Q000502:physiology; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D013266:Stilbamidines; D013373:Substance P / Q000378:metabolism; D001743:Urinary Bladder / Q000294:innervation* / Q000473:pathology*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism; D018998:Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate; D014909:Wheat Germ Agglutinins
chemical_list: C049774:2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; D005456:Fluorescent Dyes; D013266:Stilbamidines; D018998:Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate; D014909:Wheat Germ Agglutinins; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D006735:Horseradish Peroxidase